Home › Compare › JCRRF vs O

JCRRF vs O: Dividend Comparison 2026

JCRRF yields 3.22% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JCRRF wins by $590.29M in total portfolio value
10 years
JCRRF
JCRRF
● Live price
3.22%
Share price
$4.17
Annual div
$0.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$590.33M
Annual income
$557,098,169.44
Full JCRRF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — JCRRF vs O

📍 JCRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJCRRFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JCRRF + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
JCRRF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCRRF
Annual income on $10K today (after 15% tax)
$273.77/yr
After 10yr DRIP, annual income (after tax)
$473,533,444.02/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, JCRRF beats the other by $473,529,106.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCRRF + O for your $10,000?

JCRRF: 50%O: 50%
100% O50/50100% JCRRF
Portfolio after 10yr
$295.18M
Annual income
$278,551,636.09/yr
Blended yield
94.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

JCRRF
No analyst data
Altman Z
1.4
Piotroski
4/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCRRF buys
0
O buys
0
No recent congressional trades found for JCRRF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJCRRFO
Forward yield3.22%5.28% ✓
Annual dividend / share$0.13$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓15.1%
Portfolio after 10y$590.33M ✓$34.2K
Annual income after 10y$557,098,169.44 ✓$5,102.74
Total dividends collected$587.89M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: JCRRF vs O ($10,000, DRIP)

YearJCRRF PortfolioJCRRF Income/yrO PortfolioO Income/yrGap
1← crossover$11,344$644.17$10,818$608.16+$526.00 → JCRRF
2$13,504$1,365.91$11,787$741.68+$1.7K → JCRRF
3$17,489$3,039.22$12,946$911.00+$4.5K → JCRRF
4$26,070$7,356.96$14,345$1,127.94+$11.7K → JCRRF
5$48,393$20,498.67$16,056$1,409.05+$32.3K → JCRRF
6$122,906$71,124.57$18,171$1,777.83+$104.7K → JCRRF
7$469,147$337,637.75$20,820$2,268.21+$448.3K → JCRRF
8$2,910,974$2,408,986.96$24,188$2,929.90+$2.89M → JCRRF
9$31,053,709$27,938,966.99$28,533$3,837.11+$31.03M → JCRRF
10$590,325,638$557,098,169.44$34,235$5,102.74+$590.29M → JCRRF

JCRRF vs O: Complete Analysis 2026

JCRRF — Stock

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Full JCRRF Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this JCRRF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCRRF vs SCHDJCRRF vs JEPIJCRRF vs KOJCRRF vs MAINJCRRF vs STAGJCRRF vs ADCJCRRF vs NNNJCRRF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.